Quantisnow Logo
Dashboard

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $BCDA alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $BCDA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCDA

DatePrice TargetRatingAnalyst
12/20/2021$9.00Buy
HC Wainwright & Co.
More analyst ratings

$BCDA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • BioCardia Reports 2024 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clinical Trials symposium at the American College of Cardiology 2025 Scientific Sessions in Chicago (see dial-in information below). Recent Business Highlight

    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

    SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, "A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial," at the American College of Cardiology 2025 Scientific Sessions

    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

    SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled "Radial and Transendocardial Delivery Catheter" with a patent term that will expire on or after September 30, 2034. "This new patent in Japan adds to our growing patent position with respect to minimally invasive catheter-based delivery systems for cell and gene-based therapies to the heart," said Dr. Peter Altman, BioCardia CEO. "Our clinical cell therapy candidates for the treatment of ischem

    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$BCDA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BCDA
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCDA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCDA
 SEC Filings

See more

$BCDA
 Financials

Live finance-specific insights

See more

  • BioCardia Reports 2024 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clinical Trials symposium at the American College of Cardiology 2025 Scientific Sessions in Chicago (see dial-in information below). Recent Business Highlight

    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

    SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, "A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial," at the American College of Cardiology 2025 Scientific Sessions

    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

    SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration.

    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$BCDA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more